Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006:2006:83548.
doi: 10.1155/SRCM/2006/83548. Epub 2006 Nov 6.

Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution

Anne M McTiernan  1 , Anna M Cassoni, Deirdre Driver, Maria P Michelagnoli, Anne M Kilby, Jeremy S Whelan
Affiliations

Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution

Anne M McTiernan et al. Sarcoma. 2006.

Abstract

The outcome for patients with relapsed Ewing's sarcoma is poor. A retrospective analysis was carried out to identify factors associated with improved survival. Between 1992 and 2002, 114 patients presented with relapsed or progressive disease. Median time to progression/relapse was 13 months (range, 2-128). Treatment at relapse included high dose treatment (HDT) in 29 patients, and surgery or definitive radiotherapy in 29. 2 and 5-year post relapse survival (PRS) was 23.5% and 15.2%, respectively. In multivariate analysis, the most significant factors associated with improved survival were disease confined locally or to the lungs (2-year PRS, 40% versus 6%; P < .001), relapse > 18 months from diagnosis (2-year PRS, 53% versus 8%; P < .001), HDT at relapse (2-year PRS, 62% versus 11%; P < .001), and surgery and/or radiotherapy at relapse (2-year PRS, 51% versus 14%; P < .001). First treatment failure in Ewing's sarcoma is mostly fatal. Improved survival can be achieved in selective patients with aggressive treatment. These improvements are confined to those without bone or bone marrow metastases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Postrelapse survival according to all patients (n = 114).
Figure 2
Figure 2
Postrelapse survival according to high-dose therapy (HDT) at relapse (P < .001).
See this image and copyright information in PMC

References

    1. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St. Jude children's research hospital experience, 1979–1999. Cancer. 2002;94(2):561–569. - PubMed
    1. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Medical and Pediatric Oncology. 2003;40(3):141–147. - PubMed
    1. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Annals of Oncology. 2003;14(11):1654–1659. - PubMed
    1. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. Journal of Clinical Oncology. 1998;16(11):3628–3633. - PubMed
    1. Paulussen M, Craft A, Lewis I. Ewing tumor of bone—updated report of the European Intergroup Cooperative Ewing's Sarcoma Study EICESS 92. Proceedings of the American Society of Clinical Oncology. 2002;21(abstract):1568.

LinkOut - more resources